The 2013-5 Ebolavirus disease (EVD) humanitarian crisis has spurred the development of laboratory-free, point of care (POC) nucleic acid testing (NAT) solutions. EbolaCheck is an international consortium of public health, academic and biotechnology industry stakeholders aiming to deliver clinical molecular diagnostic (MDx) standard of care (SOC) testing suitable for the West African milieu within 12 months. In this article the current status of the EbolaCheck platform is discussed in the context of the current regulatory framework. Future goals to achieve differential diagnosis of hemorrhagic fever disease from <5 microliters of whole blood samples (WBS) or mucosal biofluids, in a single tube process, in under 40 minutes and with minimal operator training are presented.
Background: Clinical diagnosis of Ebolavirus disease
Ebolavirus disease (EVD) is a haemorrhagic fever disease (HFD) caused by members of the filoviridae family of RNA viruses. The filamentous Ebolavirus virion (~90 x 1000 nm) houses a 7 gene, ~19 kb genome packed in a nucleoprotein (NP) sheath. Transmission is mediated via the Ebolavirus transmembrane glycoprotein (GP) primarily via macrophage/monocytes. The glycoprotein also features immunomodulation, immune evasion and endothelial barrier disruption roles.
[1] The monocytic tropism of Ebolavirus mediates proinflammatory responses during replication that amplify infectivity and pathology, collectively resulting in the internal haemorrhage and organ failure characteristic of the later stages of disease. [2, 3] Diagnosis is extremely difficult [2, 4] as symptoms mimic other HFDs, flu, or gastrointestinal infections, which do not preclude Ebolavirus co-infection. [4, 5] Transmission risk increases in line with symptom severity, mirroring viraemia; [6] pre-symptomatic patients are not considered contagious and may remain asymptomatic for up to 21 days. [3] Confirmation of Ebolavirus as the causal disease agent requires clinical molecular diagnostic (MDx) laboratory solutions. To date, USD$100, <8 hr long, transcription polymerase chain reaction (RT-PCR) nucleic acid tests (NAT) on RNA extracts from 3.5 ml of whole blood sample (WBS) are the method of choice. [7] However, at the height of the EVD outbreak lack of capacity in West Africa Panning et al.. [10] These eventually received USFDA emergency use authorisation (EUA; EZ1 assay) or were made commercially available under the self-certification CE marking principles (Altona RealStar ® Filovirus Screen), [11] respectively.
Molecular diagnostics for infectious diseases at the point of need
Following 9/11 and the subsequent airborne viral disease pandemics, efforts were made to develop decentralised, point of care (POC) NAT's [12] . The resulting solutions, however, were not designed with resource-limited settings in mind, [13] despite the ASSURED criteria espoused by the WHO. [14] Thus, the need for a safe, cheap, simple, robust, portable and battery operated solution remained, presenting an attractive development opportunity for emerging NAT technologies. However, clinical development costs, [13] convoluted intellectual property landscapes and industry doubts over outbreak duration and return on investment potential, presented substantial obstacles. Poignantly, despite corporate social responsibility opportunities, to date, all of the major diagnostics manufacturers that engaged in the Ebola response offered primer-probe kits for existing lab-based platforms, or developed 'cassette' kits for existing, closer-topatient systems. Importantly, these cassette systems maintain for-profit pricing structures for low and middle-income countries, even following receipt of philanthropic donations in support of their development. The monetisation/investment barrier remains cornerstone to both regulator and non-government support organisation efforts. [15] Yet despite large industry indifference several academic groups and start up/spinout companies sought to address the POC clinical diagnostic need. However, they faced scepticism from some regulatory bodies regarding manufacturing capacity, quality assurance, commercial launch/support and distribution capability. 
EbolaCheck: Key principles
EbolaCheck can be divided into four sub-systems: the NAT instrument, the EVD assay, the WBS reaction formulation and the reaction consumable. Together, they aim to replace the clinical MDx standard of care (SOC) with a rapid, pointof-need, sample-to-answer format.
Low cost suitable for West Africa
A simple, patent-protected, energy and engineering-efficient method enables rapid (<2 min), single-tube access to pathogen & host nucleic acids in biofluids with no need for microfluidics. Direct compatibility with standard, cryoprotectable RT-PCR biochemistries further reduces overall cost. Crucially, EbolaCheck will be available to support the on-going, WHO-declared, EVD humanitarian crisis in Africa at cost only.
Clinical standard of care reliability
The Trombley assay sets for Ebolavirus Zaire GP and NP [9] were migrated to EbolaCheck (Trombley+) to i) minimise delays, ii) avoid complex licensing negotiations and iii) on account of emerging field performance evaluation data.
Multiplexed use of the Trombley+ assay sets also discriminate vaccinated from infected patients; NP is not found in the two most advanced EVD clinical vaccine candidates [17, 18] 
Safety
The 5 microliter WBS requirement of EbolaCheck presents a significant risk reduction to both HCW and HFD patients compared to the closed system, 3.5 ml Vacutainer ® Eclipse TM needle and Vacutainer ® sample SOC protocol. Thermal cycling is expected to destroy EVD [20] ; used, sealed consumables are nonetheless discarded as BSL4 clinical waste. The instrument is fully compatible with chlorine dioxide surface sterilisation [20] and designed against ingress of liquids or internal condensation [13] . Secure WiFi interface permits remote system checks, maintenance and full reaction data off-boarding. The random access stations also self-diagnose errors and automatically shut down to prevent misdiagnosis. 
Speed

Development timeline
Prototype design, engineering and assay development was initiated in November 2014. Internal assay standards containing the Trombley assay targets were developed in MS2 phage icosahedron (Armored RNA ® ) [21] (commercially available) and lipid bilayer enveloped HIV pseudovirus [22] (open access) formats. Although 26nm and 80-100nm in size respectively, these represent a vast cadre of viral pathogens. Thus, BSL4 study requirements have been reduced to confirmatory studies using live Ebolavirus, and yielded data supporting EbolaCheck platform utility against other viral pathogens. BSL4 studies are thus limited to performance evaluation testing against the clinical SOC NAT Trombley assay on culture preparations of Ebolavirus and fresh WBS derived from nonhuman primate models of Ebolavirus infection. In-country testing with fresh or stored patient samples is not expected on account of continued outbreak decline and current WHO priorities to established technologies. However, at least 3 instruments will be tested in West Africa using mock sample preparations to confirm system operation, portability and reliability in urban, rural and remote environments.
Future directions
Our early data support multiplexed detection and quantification potential of [3] [4] NAT targets in WBS on EbolaCheck. As positive [23] and detrimental [5] coinfections are common amongst EVD patients, expansion of multiplexing is necessary, but unlikely to exceed concomitant amplification capability need beyond 5 targets. Field data also indicate mucosal biofluids such as semen [24] , ocular fluid [25] and breast milk [26] might be viral depots in convalescence.
Interestingly, culturally acceptable alternatives such as saliva [27] and gingivalcrevicular fluid [28] , might also be of use for HFD diagnosis. Thus, demonstrating EbolaCheck compatibility with these mucosal biofluids will expand point of need monitoring and surveillance capability and introduce the opportunity for needlefree testing. Early feasibility studies indicate this may enable differential HFD diagnosis with minimal cost of goods increase. EbolaCheck, it features a 3 log, non-quantitative dynamic range in highly diluted WBS, requires sample pre-processing, multiple mechanical steps and a separate personal computer and barcode scanner. Despite >10,000 instruments placed worldwide this WHO-selected platform costs US$17,000-17,500 to eligible countries. Thus, per-unit scaled production costs are comparable to the current manufacturing cost of EbolaCheck prototypes and the Trombley+ EVD assays.
Concluding remarks
The EbolaCheck consortium has demonstrated that humanitarian crises can motivate efforts to the significant potential benefit of those in need as well as leverage development opportunities for appropriately positioned technologies from socially responsible industry with commercial interests in the West. The EbolaCheck consortium is presently seeking charitable support towards scale-up production and delivery of the first differential HFD diagnosis solution, to be provided at cost for any future WHO-declared humanitarian crises.
